Byrne, Ann
Savas, Peter http://orcid.org/0000-0001-5999-428X
Sant, Sneha
Li, Ran
Virassamy, Balaji http://orcid.org/0000-0002-7341-8104
Luen, Stephen J. http://orcid.org/0000-0001-6962-2906
Beavis, Paul A.
Mackay, Laura K.
Neeson, Paul J.
Loi, Sherene http://orcid.org/0000-0001-6137-9171
Article History
Accepted: 17 January 2020
First Online: 28 February 2020
Competing interests
: S.L.’s institution receives research funding from Bristol-Myers Squibb, Eli Lilly, Genentech, Merck, Novartis, Pfizer, Puma Biotechnology and Roche. S.L. has acted as a non-compensated consultant of AstraZeneca, Bristol-Meyers Squibb, Merck, Novartis, Pfizer, Roche-Genentech and Seattle Genetics. P.J.N. receives research funding from Advaxis, Allergan, Bristol-Myers Squibb, Compugen, Juno-Celgene and Roche-Genentech. The other authors declare no competing interests.